Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The highest-paid CEOs in the corporate world, often act as guiding forces, leading their organizations toward growth and ...

6. Leonard Schleifer (Regeneron Pharmaceuticals) – $452.9 Million Leonard Schleifer, CEO of Regeneron Pharmaceuticals, has overseen groundbreaking advancements in biopharmaceuticals. His $452.9 ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.

As the company's CEO, Leonard Schleifer, said, "We anticipate that share repurchases will remain the primary means of returning capital to shareholders." Regeneron might still increase its ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...